Diabetes drugs show no significant difference in risk of deathBMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4010 (Published 20 July 2016) Cite this as: BMJ 2016;354:i4010
- Jacqui Wise
The nine available classes of glucose lowering drugs showed no significant difference in terms of cardiovascular or all cause mortality, in a systematic review with network meta-analysis published in JAMA. The review included 301 clinical trials and nearly 120 000 adults with type 2 diabetes.1
A large number of glucose lowering drug classes are now approved for type 2 diabetes, including metformin, insulins, sulfonylureas, thiazolidinediones, dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 (GLP-1) …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial